ERYTHRODERMIC PSORIASIS
Clinical trials for ERYTHRODERMIC PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new ERYTHRODERMIC PSORIASIS trials appear
Sign up with your email to follow new studies for ERYTHRODERMIC PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial targets rare, severe skin disease
Disease control OngoingThis study is testing an experimental medication called JNJ-77242113 for people with two severe forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The main goal is to see how well the drug improves skin symptoms and overall condition over 1…
Matched conditions: ERYTHRODERMIC PSORIASIS
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial targets severe, painful skin disease
Disease control OngoingThis study is testing an investigational drug called TAK-279 in adults with two severe and rare forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). All participants will receive the drug for up to 52 weeks. The main goal is to see how well i…
Matched conditions: ERYTHRODERMIC PSORIASIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC